Last reviewed · How we verify
NCT05535803
Treatment of Laryngotracheal Stenosis Using Mesenchymal Stem Cells
Phase 2 trial testing Olfactory mucosa-derived mesenchymal stem cells in Tracheal Stenosis in 20 participants. Status unknown.
30 June 2023
Quick facts
| Lead sponsor | Institute of Biophysics and Cell Engineering of National Academy of Sciences of Belarus |
|---|---|
| Phase | Phase 2 |
| Status | Status unknown |
| Study type | INTERVENTIONAL |
| Allocation | non randomized |
| Design | parallel |
| Masking | none |
| Primary purpose | treatment |
| Enrollment | 20 |
| Start date | 1 June 2021 |
| Primary completion | 30 June 2023 |
| Estimated completion | 30 June 2023 |
| Sites | 1 location across Belarus |
Drugs / interventions tested
- Olfactory mucosa-derived mesenchymal stem cells — full drug profile →
- Patients treated according to current clinical protocols
Conditions studied
- Tracheal Stenosis — all drugs for Tracheal Stenosis →
- Laryngeal Stenosis — all drugs for Laryngeal Stenosis →
Sponsor
Institute of Biophysics and Cell Engineering of National Academy of Sciences of Belarus
Who can join
Adults 18 to 85, any sex, with Tracheal Stenosis or Laryngeal Stenosis. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
The trial evaluates the safety and efficacy of the olfactory mucosa-derived mesenchymal stem cells based therapy for the patients with chronic laryngeal and tracheal stenosis
Publications & conference data
No peer-reviewed publications indexed yet for this trial.
Verify or expand the search:
- PubMed search for NCT05535803
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other trials of Olfactory mucosa-derived mesenchymal stem cells
Trials testing the same drug.
- NCT05167552 — Treatment of Allergic Rhinitis and Chronic Polypous Rhinosinusitis With Olfactory Mucosa-derived Mesenchymal Stem Cells · Phase 1, PHASE2 · unknown
- NCT03130374 — Treatment of Laryngotracheal Stenosis Using Mesenchymal Stem Cells · Phase 1, PHASE2 · completed
Other recruiting trials for Tracheal Stenosis
Currently open trials in the same condition.
- NCT07258784 — RNA Sequencing of Discarded Tracheal Stenosis Tissue to Characterize Cellular and Molecular Pathogenesis · recruiting
- NCT06917222 — Slide Tracheoplasty Versus Tracheal Resection Anastomosis in Acquired Tracheal Stenosis · NA · recruiting
Other Institute of Biophysics and Cell Engineering of National Academy of Sciences of Belarus trials
Trials by the same sponsor.
- NCT06167564 — Allergy Diagnostic Test Based on Microchip Technology · NA · unknown
- NCT05654766 — Assesment of the Functional Activity of Platelets for the Differential Diagnosis of Thrombocytopathies · unknown
- NCT05520125 — Treatment of Patients With Bone Tissue Defects Using Mesenchymal Stem Cells Enriched by Extracellular Vesicles · Phase 1, PHASE2 · unknown
- NCT05520112 — Treatment of Recurrent Pregnancy Loss Using Mesenchymal Stem Cells · Phase 1, PHASE2 · unknown
- NCT05214014 — Treatment of Systemic Sclerosis With Autologous Regulatory Т-cells · Phase 1, PHASE2 · unknown
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT05535803 (US National Library of Medicine, public domain)
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Institute of Biophysics and Cell Engineering of National Academy of Sciences of Belarus
- Last refreshed: 10 September 2022
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05535803.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing